HFB 100204
Alternative Names: HFB-100204Latest Information Update: 25 Apr 2023
At a glance
- Originator HiFiBiO
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CXCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer
Most Recent Events
- 06 Apr 2023 Early research in Autoimmune disorders in USA (Parenteral)
- 06 Apr 2023 Early research in Cancer in USA (Parenteral)